Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution
M Sotelo, N Muñoz-Unceta, A Matorras, P Jara… - Clinical and …, 2024 - Springer
Abstract Purpose Immune checkpoint inhibitors (ICIs) have been incorporated in the
treatment of metastatic urothelial carcinoma (mUC) upon platinum-based chemotherapy …
treatment of metastatic urothelial carcinoma (mUC) upon platinum-based chemotherapy …
Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study …
AV Balar, R Dreicer, Y Loriot, JL Perez-Gracia… - 2018 - ascopubs.org
4523 Background: Platinum-based chemotherapy is a standard first-line approach for mUC,
but many pts are ineligible for cisplatin, and progression is common. Atezo (anti–PD-L1) was …
but many pts are ineligible for cisplatin, and progression is common. Atezo (anti–PD-L1) was …
Early efficacy results from atezolizumab (ATZ) with split doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma …
G de Velasco, I García-Carbonero… - 2023 - ascopubs.org
502 Background: Urothelial carcinoma (UC) commonly affects patients (pts) who are
ineligible for full doses of cisplatin-based chemotherapy (CT) due to bad performance status …
ineligible for full doses of cisplatin-based chemotherapy (CT) due to bad performance status …
Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based …
BH Bochner - European Urology, 2016 - europepmc.org
This is a comment on" Atezolizumab in patients with locally advanced and metastatic
urothelial carcinoma who have progressed following treatment with platinum-based …
urothelial carcinoma who have progressed following treatment with platinum-based …
[HTML][HTML] Atezolizumab in advanced or metastatic urothelial carcinoma after platinum-based chemotherapy: experience in real clinical practice
L García Basas, M Sánchez Cuervo… - Revista de la …, 2023 - SciELO Espana
Results: Twenty-nine patients were studied with a median follow up of 5.1 months (range 0-
21.6). Median age was 75 years in our cohort and 67 years in the IMvigor211 trial. The …
21.6). Median age was 75 years in our cohort and 67 years in the IMvigor211 trial. The …
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a …
Background The primary analysis of IMvigor130 showed a significant progression-free
survival benefit with first-line atezolizumab plus platinum-based chemotherapy (group A) …
survival benefit with first-line atezolizumab plus platinum-based chemotherapy (group A) …
Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world …
M Mencinger, D Mangaroski, U Bokal - Radiology and Oncology, 2021 - sciendo.com
Background Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel
treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic …
treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic …
Safety and efficacy of atezolizumab in understudied populations with pretreated urinary tract carcinoma: subgroup analyses of the SAUL study in real-world practice
AS Merseburger, D Castellano, T Powles… - The Journal of …, 2021 - auajournals.org
Purpose: Atezolizumab is an established treatment option for pretreated urothelial
carcinoma, demonstrating efficacy in phase II/III trials. The SAUL study enrolled a broader …
carcinoma, demonstrating efficacy in phase II/III trials. The SAUL study enrolled a broader …
[PDF][PDF] IMvigor130: a phase III study of atezolizumab with or without platinum-based chemotherapy in previously untreated metastatic urothelial carcinoma
E Grande, MD Galsky, JA Arranz Arija… - ESMO …, 2019 - medically.roche.com
0 182 (40) 173 (43) 157 (43) 1 209 (46) 187 (47) 174 (48) 2 60 (13) 40 (10) 31 (9) Bajorin
risk factor score, n (%) 0 176 (39) 162 (41) 151 (42) 1 169 (37) 149 (37) 134 (37) 2 and/or …
risk factor score, n (%) 0 176 (39) 162 (41) 151 (42) 1 169 (37) 149 (37) 134 (37) 2 and/or …
Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma
Atezolizumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting
human programmed death‐ligand 1 (PD‐L1), is US Food and Drug Administration (FDA) …
human programmed death‐ligand 1 (PD‐L1), is US Food and Drug Administration (FDA) …